BIO-TECHNE Corp Cost of Revenue
BIO-TECHNE Corp (TECH) reported Cost of Revenue of $415.97 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-24.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-24
- BIO-TECHNE Corp cost of goods and services sold for the quarter ending 2026-06-30 was $109.80M, a 7.07% decline year-over-year.
- BIO-TECHNE Corp cost of goods and services sold for the quarter ending 2026-03-31 was $103.13M, a 1.48% increase year-over-year.
- BIO-TECHNE Corp cost of goods and services sold for the quarter ending 2025-12-31 was $104.60M, a 1.41% increase year-over-year.
- BIO-TECHNE Corp cost of goods and services sold for the quarter ending 2025-09-30 was $98.44M, a 7.51% decline year-over-year.
- BIO-TECHNE Corp cost of goods and services sold for fiscal 2026 was $415.97M, a 3.12% decline from fiscal 2025.
- BIO-TECHNE Corp cost of goods and services sold for fiscal 2025 was $429.36M, a 10.28% increase from fiscal 2024.
- BIO-TECHNE Corp cost of goods and services sold for fiscal 2024 was $389.33M, a 6.12% increase from fiscal 2023.
- BIO-TECHNE Corp cost of goods and services sold for fiscal 2023 was $366.89M, a 5.09% increase from fiscal 2022.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 6 month as first filed | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 9 month as first filed | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $109.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-24 | $212.93M derived: sum of 2 quarters · filed 2026-08-24 | $317.52M derived: sum of 3 quarters · filed 2026-08-24 | $415.97M 10-K · filed 2026-08-24 | |||
| 2026-03-31 | $103.13M 10-Q · filed 2026-05-06 | $207.73M derived: sum of 2 quarters · filed 2026-05-06 | $306.17M 10-Q · filed 2026-05-06 | $424.32M derived: sum of 4 quarters · filed 2026-08-24 | |||
| 2025-12-31 | $104.60M 10-Q · filed 2026-02-04 | $203.04M 10-Q · filed 2026-02-04 | $321.19M derived: sum of 3 quarters · filed 2026-08-24 | $422.82M derived: sum of 4 quarters · filed 2026-08-24 | |||
| 2025-09-30 | $98.44M 10-Q · filed 2025-11-05 | $216.59M derived: sum of 2 quarters · filed 2026-08-24 | $318.22M derived: sum of 3 quarters · filed 2026-08-24 | $421.37M derived: sum of 4 quarters · filed 2026-08-24 | |||
| 2025-06-30 | $118.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-24 | $219.78M derived: sum of 2 quarters · filed 2026-08-24 | $322.92M derived: sum of 3 quarters · filed 2026-08-24 | $429.36M 10-K · filed 2026-08-24 | |||
| 2025-03-31 | $101.63M 10-Q · filed 2026-05-06 | $204.77M derived: sum of 2 quarters · filed 2026-05-06 | $311.21M 10-Q · filed 2026-05-06 | $413.96M derived: sum of 4 quarters · filed 2026-08-24 | |||
| 2024-12-31 | $103.14M 10-Q · filed 2026-02-04 | $209.59M 10-Q · filed 2026-02-04 | $312.34M derived: sum of 3 quarters · filed 2026-08-24 | $411.17M derived: sum of 4 quarters · filed 2026-08-24 | |||
| 2024-09-30 | $106.44M 10-Q · filed 2025-11-05 | $209.19M derived: sum of 2 quarters · filed 2026-08-24 | $308.02M derived: sum of 3 quarters · filed 2026-08-24 | $404.03M derived: sum of 4 quarters · filed 2026-08-24 | |||
| 2024-06-30 | $102.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-24 | $201.58M derived: sum of 2 quarters · filed 2026-08-24 | $297.59M derived: sum of 3 quarters · filed 2026-08-24 | $389.33M 10-K · filed 2026-08-24 | |||
| 2024-03-31 | $98.83M 10-Q · filed 2025-05-08 | $194.84M derived: sum of 2 quarters · filed 2025-05-08 | $286.58M 10-Q · filed 2025-05-08 | $383.21M derived: sum of 4 quarters · filed 2025-08-22 | |||
| 2023-12-31 | $96.01M 10-Q · filed 2025-02-06 | $187.75M 10-Q · filed 2025-02-06 | $284.38M derived: sum of 3 quarters · filed 2025-08-22 | $376.36M derived: sum of 4 quarters · filed 2025-08-22 | |||
| 2023-09-30 | $91.74M 10-Q · filed 2024-11-05 | $188.37M derived: sum of 2 quarters · filed 2025-08-22 | $280.35M derived: sum of 3 quarters · filed 2025-08-22 | $368.57M derived: sum of 4 quarters · filed 2025-08-22 | |||
| 2023-06-30 | $96.62M derived: 10-K 12 month − 10-Q 9 month · filed 2025-08-22 | $188.61M derived: sum of 2 quarters · filed 2025-08-22 | $276.83M derived: sum of 3 quarters · filed 2025-08-22 | $366.89M 10-K · filed 2025-08-22 | |||
| 2023-03-31 | $91.98M 10-Q · filed 2024-05-06 | $180.21M derived: sum of 2 quarters · filed 2024-05-06 | $270.26M 10-Q · filed 2024-05-06 | $358.14M derived: sum of 4 quarters · filed 2024-08-22 | |||
| 2022-12-31 | $88.22M 10-Q · filed 2024-02-07 | $178.28M 10-Q · filed 2024-02-07 | $266.16M derived: sum of 3 quarters · filed 2024-08-22 | $355.08M derived: sum of 4 quarters · filed 2024-08-22 | |||
| 2022-09-30 | $90.06M 10-Q · filed 2023-11-07 | $177.94M derived: sum of 2 quarters · filed 2024-08-22 | $266.86M derived: sum of 3 quarters · filed 2024-08-22 | $352.44M derived: sum of 4 quarters · filed 2024-08-22 | |||
| 2022-06-30 | $87.88M derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-22 | $176.80M derived: sum of 2 quarters · filed 2024-08-22 | $262.38M derived: sum of 3 quarters · filed 2024-08-22 | $349.10M 10-K · filed 2024-08-22 | |||
| 2022-03-31 | $88.92M 10-Q · filed 2023-05-08 | $174.50M derived: sum of 2 quarters · filed 2023-05-08 | $261.23M 10-Q · filed 2023-05-08 | $344.31M derived: sum of 4 quarters · filed 2023-08-23 | |||
| 2021-12-31 | $85.58M 10-Q · filed 2023-02-07 | $172.31M 10-Q · filed 2023-02-07 | $255.39M derived: sum of 3 quarters · filed 2023-08-23 | $330.67M derived: sum of 4 quarters · filed 2023-08-23 | |||
| 2021-09-30 | $86.72M 10-Q · filed 2022-11-07 | $169.81M derived: sum of 2 quarters · filed 2023-08-23 | $245.08M derived: sum of 3 quarters · filed 2023-08-23 | $318.44M derived: sum of 4 quarters · filed 2023-08-23 | |||
| 2021-06-30 | $83.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-08-23 | $158.36M derived: sum of 2 quarters · filed 2023-08-23 | $231.72M derived: sum of 3 quarters · filed 2023-08-23 | $298.18M 10-K · filed 2023-08-23 | |||
| 2021-03-31 | $75.28M 10-Q · filed 2022-05-09 | $148.63M derived: sum of 2 quarters · filed 2022-05-09 | $215.10M 10-Q · filed 2022-05-09 | $277.62M derived: sum of 4 quarters · filed 2022-05-09 | |||
| 2020-12-31 | $73.35M 10-Q · filed 2022-02-07 | $139.82M 10-Q · filed 2022-02-07 | $202.34M derived: sum of 3 quarters · filed 2022-02-07 | $266.96M derived: sum of 4 quarters · filed 2022-02-07 | |||
| 2020-09-30 | $66.47M 10-Q · filed 2021-11-08 | $128.99M derived: sum of 2 quarters · filed 2021-11-08 | $193.60M derived: sum of 3 quarters · filed 2021-11-08 | $257.14M derived: sum of 4 quarters · filed 2021-11-08 | |||
| 2020-06-30 | $62.52M 10-K · filed 2020-08-26 | $127.14M derived: sum of 2 quarters · filed 2021-05-07 | $190.67M derived: sum of 3 quarters · filed 2021-05-07 | $255.50M 10-K · filed 2022-08-24 | |||
| 2020-03-31 | $64.62M 10-Q · filed 2021-05-07 | $128.15M derived: sum of 2 quarters · filed 2021-05-07 | $192.98M 10-Q · filed 2021-05-07 | $256.38M derived: sum of 4 quarters · filed 2021-05-07 | |||
| 2019-12-31 | $63.53M 10-Q · filed 2021-02-08 | $128.36M 10-Q · filed 2021-02-08 | $191.76M derived: sum of 3 quarters · filed 2021-02-08 | $252.02M derived: sum of 4 quarters · filed 2021-02-08 | |||
| 2019-09-30 | $64.83M 10-Q · filed 2020-11-09 | $128.23M derived: sum of 2 quarters · filed 2020-11-09 | $188.49M derived: sum of 3 quarters · filed 2020-11-09 | $249.98M derived: sum of 4 quarters · filed 2020-11-09 | |||
| 2019-06-30 | $63.41M 10-K · filed 2020-08-26 | $123.66M derived: sum of 2 quarters · filed 2020-08-26 | $185.15M derived: sum of 3 quarters · filed 2020-08-26 | $240.51M 10-K · filed 2021-08-25 | |||
| 2019-03-31 | $60.25M 10-K · filed 2020-08-26 | $121.74M derived: sum of 2 quarters · filed 2020-08-26 | $177.11M 10-Q · filed 2020-05-11 | $235.18M derived: sum of 4 quarters · filed 2020-08-26 | |||
| 2018-12-31 | $61.49M 10-K · filed 2020-08-26 | $116.86M 10-Q · filed 2020-02-06 | $174.93M derived: sum of 3 quarters · filed 2020-08-26 | $228.65M derived: sum of 4 quarters · filed 2020-08-26 | |||
| 2018-09-30 | $55.37M 10-K · filed 2020-08-26 | $113.44M derived: sum of 2 quarters · filed 2020-08-26 | $167.15M derived: sum of 3 quarters · filed 2020-08-26 | $219.47M derived: sum of 4 quarters · filed 2020-08-26 | |||
| 2018-06-30 | $58.07M 10-K/A · filed 2019-11-06 | $111.79M derived: sum of 2 quarters · filed 2019-11-06 | $164.10M derived: sum of 3 quarters · filed 2019-11-06 | $210.85M 10-K · filed 2020-08-26 | |||
| 2018-03-31 | $53.71M 10-K/A · filed 2019-11-06 | $106.03M derived: sum of 2 quarters · filed 2019-11-06 | $152.78M 10-Q · filed 2019-05-07 | $206.98M derived: sum of 4 quarters · filed 2019-11-06 | |||
| 2017-12-31 | $52.32M 10-K/A · filed 2019-11-06 | $99.06M 10-Q · filed 2019-02-07 | $153.27M derived: sum of 3 quarters · filed 2019-11-06 | $200.63M derived: sum of 4 quarters · filed 2019-11-06 | |||
| 2017-09-30 | $46.74M 10-K/A · filed 2019-11-06 | $100.95M derived: sum of 2 quarters · filed 2019-11-06 | $148.31M derived: sum of 3 quarters · filed 2019-11-06 | $191.97M derived: sum of 4 quarters · filed 2019-11-06 | |||
| 2017-06-30 | $54.21M 10-K · filed 2018-08-27 | $101.56M derived: sum of 2 quarters · filed 2018-08-27 | $145.23M derived: sum of 3 quarters · filed 2018-08-27 | $188.46M 10-K/A · filed 2019-11-06 | |||
| 2017-03-31 | $47.35M 10-K · filed 2018-08-27 | $49.85M 10-Q · filed 2017-05-10 | $91.02M derived: sum of 2 quarters · filed 2018-08-27 | $134.26M 10-Q · filed 2018-05-09 | $142.69M 10-Q · filed 2017-05-10 | $179.32M derived: sum of 4 quarters · filed 2018-08-27 | |
| 2016-12-31 | $43.66M 10-K · filed 2018-08-27 | $46.73M 10-Q · filed 2017-02-09 | $86.90M 10-Q · filed 2018-02-08 | $92.84M 10-Q · filed 2017-02-09 | $131.97M derived: sum of 3 quarters · filed 2018-08-27 | $172.95M derived: sum of 4 quarters · filed 2018-08-27 | |
| 2016-09-30 | $43.24M 10-K · filed 2018-08-27 | $46.11M 10-Q · filed 2016-11-09 | $88.31M derived: sum of 2 quarters · filed 2018-08-27 | $129.29M derived: sum of 3 quarters · filed 2018-08-27 | $168.61M derived: sum of 4 quarters · filed 2018-08-27 | ||
| 2016-06-30 | $45.07M 10-K · filed 2017-09-07 | $86.05M derived: sum of 2 quarters · filed 2017-09-07 | $125.37M derived: sum of 3 quarters · filed 2017-09-07 | $162.36M 10-K · filed 2018-08-27 | |||
| 2016-03-31 | $40.98M 10-K · filed 2017-09-07 | $80.30M derived: sum of 2 quarters · filed 2017-09-07 | $117.29M 10-Q · filed 2017-05-10 | $155.87M derived: sum of 4 quarters · filed 2017-09-07 | |||
| 2015-12-31 | $39.32M 10-K · filed 2017-09-07 | $76.31M 10-Q · filed 2017-02-09 | $114.89M derived: sum of 3 quarters · filed 2017-09-07 | $149.66M derived: sum of 4 quarters · filed 2017-09-07 | |||
| 2015-09-30 | $36.99M 10-K · filed 2017-09-07 | $75.56M derived: sum of 2 quarters · filed 2017-09-07 | $110.34M derived: sum of 3 quarters · filed 2017-09-07 | $146.55M derived: sum of 4 quarters · filed 2017-09-07 | |||
| 2015-06-30 | $38.58M derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-07 | $73.35M derived: sum of 2 quarters · filed 2017-09-07 | $109.56M derived: sum of 3 quarters · filed 2017-09-07 | $144.97M 10-K · filed 2017-09-07 | |||
| 2015-03-31 | $34.78M 10-Q · filed 2016-05-10 | $70.98M derived: sum of 2 quarters · filed 2016-05-10 | $106.39M 10-Q · filed 2016-05-10 | $135.32M derived: sum of 4 quarters · filed 2016-08-29 | |||
| 2014-12-31 | $36.20M 10-Q · filed 2016-02-09 | $71.62M 10-Q · filed 2016-02-09 | $100.55M derived: sum of 3 quarters · filed 2016-08-29 | $127.99M derived: sum of 4 quarters · filed 2016-08-29 | |||
| 2014-09-30 | $35.41M 10-Q · filed 2015-11-09 | $64.34M derived: sum of 2 quarters · filed 2016-08-29 | $91.78M derived: sum of 3 quarters · filed 2016-08-29 | $117.21M derived: sum of 4 quarters · filed 2016-08-29 | |||
| 2014-06-30 | $28.93M derived: 10-K 12 month − 10-Q 9 month · filed 2016-08-29 | $56.37M derived: sum of 2 quarters · filed 2016-08-29 | $81.80M derived: sum of 3 quarters · filed 2016-08-29 | $106.35M 10-K · filed 2016-08-29 | |||
| 2014-03-31 | $27.44M 10-Q · filed 2015-05-11 | $52.87M derived: sum of 2 quarters · filed 2015-05-11 | $77.42M 10-Q · filed 2015-05-11 | $97.78M derived: sum of 4 quarters · filed 2015-08-31 | |||
| 2013-12-31 | $25.42M 10-Q · filed 2015-02-09 | $49.98M 10-Q · filed 2015-02-09 | $70.34M derived: sum of 3 quarters · filed 2015-08-31 | $90.18M derived: sum of 4 quarters · filed 2015-08-31 | |||
| 2013-09-30 | $24.55M 10-Q · filed 2014-11-10 | $44.91M derived: sum of 2 quarters · filed 2015-08-31 | $64.76M derived: sum of 3 quarters · filed 2015-08-31 | $84.58M derived: sum of 4 quarters · filed 2015-08-31 | |||
| 2013-06-30 | $20.36M derived: 10-K 12 month − 10-Q 9 month · filed 2015-08-31 | $40.20M derived: sum of 2 quarters · filed 2015-08-31 | $60.02M derived: sum of 3 quarters · filed 2015-08-31 | $79.47M 10-K · filed 2015-08-31 | |||
| 2013-03-31 | $19.84M 10-Q · filed 2014-05-12 | $39.66M derived: sum of 2 quarters · filed 2014-05-12 | $59.11M 10-Q · filed 2014-05-12 | $78.92M derived: sum of 4 quarters · filed 2014-08-29 | |||
| 2012-12-31 | $19.82M 10-Q · filed 2014-02-04 | $39.26M 10-Q · filed 2014-02-04 | $59.08M derived: sum of 3 quarters · filed 2014-08-29 | $79.32M derived: sum of 4 quarters · filed 2014-08-29 | |||
| 2012-09-30 | $19.44M 10-Q · filed 2013-11-12 | $39.26M derived: sum of 2 quarters · filed 2014-08-29 | $59.50M derived: sum of 3 quarters · filed 2014-08-29 | $78.99M derived: sum of 4 quarters · filed 2014-08-29 | |||
| 2012-06-30 | $19.82M derived: 10-K 12 month − 10-Q 9 month · filed 2014-08-29 | $40.05M derived: sum of 2 quarters · filed 2014-08-29 | $59.55M derived: sum of 3 quarters · filed 2014-08-29 | $78.76M 10-K · filed 2014-08-29 | |||
| 2012-03-31 | $20.24M 10-Q · filed 2013-05-10 | $39.73M derived: sum of 2 quarters · filed 2013-05-10 | $58.94M 10-Q · filed 2013-05-10 | $77.35M derived: sum of 4 quarters · filed 2013-08-29 | |||
| 2011-12-31 | $19.49M 10-Q · filed 2013-02-11 | $38.70M 10-Q · filed 2013-02-11 | $57.11M derived: sum of 3 quarters · filed 2013-08-29 | $73.05M derived: sum of 4 quarters · filed 2013-08-29 | |||
| 2011-09-30 | $19.21M 10-Q · filed 2012-11-09 | $37.62M derived: sum of 2 quarters · filed 2013-08-29 | $53.56M derived: sum of 3 quarters · filed 2013-08-29 | $68.88M derived: sum of 4 quarters · filed 2013-08-29 | |||
| 2011-06-30 | $18.41M derived: 10-K 12 month − 10-Q 9 month · filed 2013-08-29 | $34.35M derived: sum of 2 quarters · filed 2013-08-29 | $49.67M derived: sum of 3 quarters · filed 2013-08-29 | $65.03M 10-K · filed 2013-08-29 | |||
| 2011-03-31 | $15.94M 10-Q · filed 2012-05-10 | $15.83M 10-Q · filed 2011-05-10 | $31.27M derived: sum of 2 quarters · filed 2012-05-10 | $46.62M 10-Q · filed 2012-05-10 | $46.29M 10-Q · filed 2011-05-10 | $60.89M derived: sum of 4 quarters · filed 2012-08-29 | |
| 2010-12-31 | $15.33M 10-Q · filed 2012-02-07 | $15.22M 10-Q · filed 2011-02-09 | $30.68M 10-Q · filed 2012-02-07 | $30.46M 10-Q · filed 2011-02-09 | $44.95M derived: sum of 3 quarters · filed 2012-08-29 | $59.34M derived: sum of 4 quarters · filed 2012-08-29 | |
| 2010-09-30 | $15.35M 10-Q · filed 2011-11-09 | $15.24M 10-Q · filed 2010-11-09 | $29.62M derived: sum of 2 quarters · filed 2012-08-29 | $44.02M derived: sum of 3 quarters · filed 2012-08-29 | $57.35M derived: sum of 4 quarters · filed 2012-08-29 | ||
| 2010-06-30 | $14.27M derived: 10-K 12 month − 10-Q 9 month · filed 2012-08-29 | $28.67M derived: sum of 2 quarters · filed 2012-08-29 | $42.00M derived: sum of 3 quarters · filed 2012-08-29 | $54.90M 10-K · filed 2012-08-29 | |||
| 2010-03-31 | $14.40M 10-Q · filed 2011-05-10 | $27.73M derived: sum of 2 quarters · filed 2011-05-10 | $40.63M 10-Q · filed 2011-05-10 | ||||
| 2009-12-31 | $13.33M 10-Q · filed 2011-02-09 | $26.23M 10-Q · filed 2011-02-09 | |||||
| 2009-09-30 | $12.90M 10-Q · filed 2010-11-09 | ||||||
| 2009-06-30 | $55.92M 10-K · filed 2011-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |